Health Care

Discover how Daiichi Sankyo’s latest earnings forecast signals rising profits, expanding revenue, and strong pharma growth ahead of its April 2026 financial release.

Quest Diagnostics’ latest earnings reveal a shift toward high‑margin, tech‑enabled testing—underlying growth, cost‑efficiency, and regulatory challenges that could reshape its valuation and investor outlook.

AustralianSuper’s stake drop and Cochlear’s new ASX 50 ETF spot show how institutional shifts and passive exposure shape hearing‑aid growth prospects and governance dynamics.

Boston Scientific’s latest clinical data on FARAPULSE, WATCHMAN, and EMBLEM shows higher success and lower risk, boosting reimbursement prospects and market share in cardiac devices.

Intuitive Surgical’s analyst coverage shows steady growth amid rising competition, highlighting the da Vinci system’s innovation, market leadership, and future challenges.

Discover how Sartorius Stedim Biotech’s Q4 2026 results reveal steady EPS growth, 14 % revenue lift, and a digital‑sustainability edge in a tight bioprocessing market.

Unilever’s pivot to wellness‑centric consumer health, backed by science‑based nutraceuticals, boosts margins and meets rising health‑conscious demand.

UHS Q1 earnings: analysts predict EPS and revenue growth fueled by stable Medicare reimbursement, tech upgrades, and quality‑focused strategies, boosting investor confidence.

Regeneron’s next‑generation biologics strategy blends advanced protein engineering, AI‑driven discovery, and scalable manufacturing—fueling growth in oncology, immunology, and its core eye‑care hits.

Eli Lilly’s Q1 earnings will reveal if Foundayo’s slow GLP‑1 adoption and its $7 billion Kelonia CAR‑T deal can sustain growth and diversify revenue in 2024.